RESUMO
Several hydrogenated derivatives of the potent NMDA antagonist 1 have been prepared and evaluated as competitive inhibitors of [3H]-1 binding. These compounds were also tested for their ability to act as noncompetitive antagonists of NMDA in vitro. These studies indicate that two aromatic rings are not strictly required for high-affinity binding or NMDA antagonism.
Assuntos
Anticonvulsivantes/farmacologia , Ácido Aspártico/análogos & derivados , Dibenzocicloeptenos/farmacologia , Animais , Ácido Aspártico/antagonistas & inibidores , Dibenzocicloeptenos/síntese química , Dibenzocicloeptenos/metabolismo , Maleato de Dizocilpina , Técnicas In Vitro , Conformação Molecular , N-Metilaspartato , Ratos , Receptores de N-Metil-D-Aspartato , Receptores de Neurotransmissores/efeitos dos fármacos , Relação Estrutura-AtividadeRESUMO
A series of 73 dibenzo[a,d]cycloalkenimines were synthesized and evaluated for their ability to displace (+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]-(+)-10) from its specific binding site on rat cortical membranes. A number of the more active compounds (Ki ranging from 0.006 to 0.21 microM) were evaluated for N-methyl-D-aspartate (NMDA) antagonist activity in the rat cortical slice (Kb ranging from 0.08 to 0.9 microM) and anticonvulsant activity in the mouse against NMDA induced convulsions. The ED50 values ranged from 0.22 to 7.76 mg/kg and correlated reasonably well with the Kb determination. In the dibenzo[a,d]cyclohepten-5,10-imine series, the (+)-5S,10R enantiomer displayed consistently higher levels of biological activity. While substitution at the 3-position of (+)-10 with electronegative atoms generally increased in vitro activity, a loss of potency relative to (+)-10 (MK-801) was observed in vivo for all of the compounds tested.